CLS signs agreement with ROSE Urology for treatment of prostate cancer patients with TRANBERG Thermal Therapy System
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) announces today that their US subsidiary CLS Americas has signed an agreement with ROSE Urology, LLC, in Florida, the US, that will use TRANBERG Thermal Therapy system for treatment of prostate cancer patients.
Under CLS's Mobile Services Provider, CLS provides its FDA 510(k) cleared TRANBERG Thermal Therapy System with consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during treatment of prostate cancer patients.
ROSE Urology is focused on providing its patients with premier urologic care using state-of-the art technology to create the best outcomes and patient experience possible.
“Our Mobile Service Provider model enables ROSE Urology and other leading clinics to gain quick access to the TRANBERG Thermal Therapy System with no capex requirements. Being able to choose from different services and pay on a fee per procedure basis, is a cost efficient and flexible alternative for clients wanting to provide their patients with minimal invasive and precise laser ablation treatments of prostate cancer,” says Dan J. Mogren, CEO, CLS.
For further information, please contact:
Dan J. Mogren, CEO Clinical Laserthermia Systems AB
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se